cancer diagnostics Articles
-
Immobilising of anti-HPV18 and E. coli O157:H7 antibodies on magnetic silica-coated Fe
3O4for early diagnosis of cervical cancer and diarrhoeThis paper presents the synthesis and properties of magnetic silica-coated Fe3O4 nanoparticles. Uncoated Fe3O4 nanoparticles with an average diameter of 9-16 nm and saturation magnetisation of around 66 emu/g were first prepared by co-precipitation method. After being coated by SiO2 using the sol-gel method, the diameters of the coated particles ranged from 29 nm to 230 nm and their corresponding ...
-
Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancer
Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America. The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform. The study is supported in part by the Alberta Innovates AICE-Concepts Program with a ...
-
AIM movers: Positive erectile dysfunction news from Futura and Shoe Zone continues to surprise
Futura Medical (LON: FUM) says that the clinical study for the MED3000 topical gel erectile dysfunction treatment has met its primary and secondary endpoints. They showed an improvement in erectile function and a highly statistic improvement in the onset of action at 10 minutes. There were limited side effects with 4.3% of patient suffering headaches and a further 4.3% nausea, which is much ...
-
INOVIQ study validates the use of SubB2M as an aid in diagnosing malignant melanoma
Data from 144 tissue samples in the feasibility study demonstrated that SubB2M immunohistochemistry detected melanoma with 91% sensitivity and discriminated between malignant melanoma and benign skin lesions. SubB2M-based immunohistochemistry applications represent a new product opportunity for SubB2M in the $1.9b immunohistochemistry market. INOVIQ Ltd (ASX:IIQ) has successfully completed ...
By INOVIQ Ltd
-
Adaptive MRD Chief Commercial Officer Nitin Sood Shares How His Personal Journey Has Shaped His Career Path
Here at Adaptive, putting the patient first is a core value—a philosophy that deeply resonates with me. Similar to many of my fellow Adapters, my inspiration is personal and I’m excited by the tremendous potential impact we can have on human lives through the work we’re doing in our Immune Medicine and MRD businesses. Growing up in New Delhi, India, my father worked for a ...
-
Unveiling the Role of CDH1 Protein in Cancer and Future Research Directions
Introduction CDH1, also known as E-cadherin, is a crucial protein involved in cell adhesion and plays a significant role in various biological processes. In recent years, researchers have focused on understanding the functions of CDH1 and its implications in cancer development. This blog post aims to shed light on what CDH1 protein does, its role in cancer, and the future research directions in ...
-
Automatically Diagnosing HER2 Amplification Status for Breast Cancer Patients Using Large FISH Images
Fluorescence in situ hybridization (FISH) is a technique that prepares acceptable results for molecular imaging biomarkers to precisely and dependably detect and diagnose disorders which are sign of cancers. Since contemporary manual FISH signal analysis is low-effective and inconsistent, it is an attractive research area to develop automated FISH image scanning systems and computer-aided ...
-
EDAP Announces Exclusive Worldwide Distribution Rights to Exact Imaging’s Micro-Ultrasound Technologies
Exact Imaging is a leading developer of ultra-high-resolution micro-ultrasound diagnostic technologies Micro-ultrasound ExactVu™ is the only ultrasound-based imaging tool with published data demonstrating prostate cancer diagnostic capabilities similar to MRI Combination of Exact Imaging’s micro-ultrasound and EDAP’s Focal One® represents the most complete offering for ...
-
A Reflection on Blood Cancer Awareness Month: Patient Spotlight
As September and Blood Cancer Awareness Month wrap up, we want to reflect on a memorable conversation with Karen Thomas, a woman who received clonoSEQ® testing, and her physician, Dr. Hazma Hashmi, a hematologist-oncologist from the Medical University of South Carolina. At Adaptive, we know our diagnostic tests provide key information that help physicians and patients make treatment ...
-
Breaking Barriers – Past and Current: Celebrating the Legacy of Dr. Clarice Reid, Pioneer in Sickle Cell Research, Biomark Diagnostics
Dr. Clarice Reid was a trailblazer in the field of sickle cell disease, dedicating her life and career to improving the lives of those affected by this debilitating genetic blood disorder. As a pioneering black woman in the field of medicine and science, Dr. Reid’s work has made a significant impact on our understanding of this condition and has paved the way for the development of ...
-
A Historic Breakthrough in Physics for Cancer and Heart Patients
DENVER, CO / ACCESSWIRE / September 5, 2018 / A significant milestone has been reached in nuclear fusion by MIFTEC Laboratories, Inc. when they recently exceeded 1010 neutrons per pulse power level. This level of neutron flux is close to that which is needed to commercially produce radionuclides for nuclear medicine, and validates previous claims regarding the commercial viability of their ...
-
Israeli hospital pilots rapid diagnostics of blood cancer with Sight Diagnostics
Israeli-founded firm Sight Diagnostics, the company that uses AI and cutting-edge hardware to deliver rapid, complete blood count results, has signed a new research agreement with Jerusalem’s Shaare Zedek Medical Center to identify the possibility of blood cancer using a combination of images and data collected from Sight’s OLO device and patient clinical information provided by the ...
-
HPV-16 E7-Specific Cellular Immune Response
HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study High-risk human papillomavirus (HPV) infection is the cause of almost all cervical cancers. HPV16 is one of the main risk subtypes. Although screening programs have greatly reduced the prevalence of cervical cancer in ...
-
Global Partnership to Improve Diagnostic Accuracy of Breast Cancer
Femtech World featured our partnership with PathPresenter to distribute the 4D Q-plasia OncoReader Breast within PathPresenter’s ClinPx Clinical Workflow Platform in their magazine. The primary purpose of integrating 4D Path’s proprietary algorithms within the PathPresenter ClinPx platform is to potentially improve the throughput, reliability, and quality of consultations ...
By 4D Path Inc.
-
Enzyme for Diagnosis: Revolutionizing Medical Diagnostics
Enzymes are biological catalysts that accelerate chemical reactions in living organisms. In recent years, enzymes have been increasingly utilized in medical diagnostics, leading to significant advancements in disease detection and management. Enzyme-based diagnostic tools have revolutionized the healthcare industry, offering numerous benefits such as increased accuracy, sensitivity, and speed. ...
-
New blood-based CRC test is more than 90% accurate, study says
A study of Universal Diagnostics' blood-based colorectal cancer test found it was more than 90 percent accurate, the company announced June 3. The blood test was found to detect colorectal cancer with 92 percent sensitivity and 97 percent specificity. It also was shown to have 89 percent sensitivity and 97 percent specificity detecting early-stage cancer. The test uses single target sequence ...
-
Raman ‘optical biopsy’ of human breast cancer
Abstract Raman imaging (RI) is a novel method of medical diagnostics of human breast cancer and has a potential to become a routine optical biopsy. Up to date the present study is the most statistically reliable Raman analysis based on data of normal, benign, and cancerous breast tissues for 146 patients. This paper present the first Raman ‘optical biopsy’ images of the normal and ...
-
Spanish Cancer Company Universal Dx to Commercialize Methylation Method for Lung Cancer Detection
NEW YORK - Spanish cancer research firm Universal Diagnostics is gearing up to commercialize a liquid biopsy test that applies methylation biomarkers to detect lung cancer, based on data presented at the International Association for the Study of Lung Cancer 2020 World Conference for Lung Cancer (WCLC) last month. The Seville-based firm also expects to release clinical data on its next ...
-
CD Genomics Perspective: The Application of RNA-Seq and DNA-Seq in Cancer Research
Clinicians can make better diagnostic and treatment decisions using the data obtained by next-generation sequencing (NGS) technologies. Breast cancers, for example, have typically been diagnosed using mammography, physical exam, and histology. Genetics became more significant after the discoveries of oncogenes and other biomarkers. Today, commercially available microarray-based tests enable more ...
By CD Genomics
-
Detecting Fusion Transcripts by RNA Sequencing in Screening Tumors
What is fusion gene? What is Chimeric RNAs? A fusion gene is a chimeric gene formed by the fusion of partial sequences of two genes, usually due to chromosomal translocations or deletions. These chimeric genes can form abnormal transcripts or proteins in subsequent biological processes, which can lead to or promote the development of tumors. For example, in chronic granulocytic leukemia, ...
By CD Genomics
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you